The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
Georgina Long
Advertisement
Long is the medical director of Melanoma Institute Australia (MIA), and chair of melanoma medical oncology and translational research at MIA and Royal North Shore Hospital, The University of Sydney.
Articles by Georgina Long
Advertisement
Latest Updated Articles
Clinical Trial to Evaluate Opdivo, Opdualag in GlioblastomaPublished: March 27th 2025 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer
2
FDA Approves Hyrnuo in Some with Locally Advanced/Metastatic NSCLC
3
FDA Accepts NDA for Zidesamtinib in Previously Treated ROS1+ NSCLC
4
FDA Grants Fast Track Status to New Gastric Cancer Treatment
5
